Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on February 4, 2005, to report on a significant legal development. The United States District Court for the Southern District of New York denied the company's motion to dismiss a consolidated amended complaint in a purported class action securities lawsuit. This lawsuit was initially filed in May 2003. Regeneron maintains its belief that the lawsuit is without merit and has stated its intention to defend the action vigorously. This denial of dismissal means the securities litigation will proceed, and investors should monitor further developments in this case as it progresses through the legal system. The company's position remains one of strong defense against these claims.
Key Highlights
- 1Regeneron Pharmaceuticals, Inc. (REGN) is facing a securities class action lawsuit.
- 2The company's motion to dismiss the lawsuit was denied by the U.S. District Court for the Southern District of New York on February 1, 2005.
- 3The lawsuit was originally filed in May 2003.
- 4Regeneron asserts that the lawsuit is without merit.
- 5The company intends to vigorously defend itself against the claims.
- 6The denial of the motion to dismiss means the litigation will continue.
Frequently Asked Questions
The main event reported is the denial of Regeneron Pharmaceuticals, Inc.'s motion to dismiss a consolidated amended complaint in a securities class action lawsuit filed against the company and certain officers and directors.
Regeneron believes the lawsuit is without merit and intends to defend itself vigorously.
The denial of the motion to dismiss means that the securities class action lawsuit will proceed. The case will now move forward through the legal process, potentially involving further discovery, motions, and potentially a trial.
The consolidated amended complaint stems from a securities lawsuit first commenced against the company in May 2003.